• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SANUWAVE Health Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

    5/21/25 5:11:46 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care
    Get the next $SNWV alert in real time by email
    snwv-20250512
    FALSE000141766300014176632025-05-122025-05-12
    1
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K/A
    Amendment No. 1
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported)May 12, 2025
    SANUWAVE Health, Inc.
    (Exact name of registrant as specified in its charter)
    Nevada000-5298520-1176000
    (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
    11495 Valley View Road,Eden Prairie,Minnesota55344
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code(952)656-1029
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)
    Name of each exchange on which
    registered
    Common stock, par value $0.001 per shareSNWVThe Nasdaq Stock Market LLC

    Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
    1

    2
    Explanatory Note

    This Current Report on Form 8-K/A (the “Report”) supplements the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 15, 2025 (the “Original Form 8-K”) by Sanuwave Health, Inc. (the “Company”) disclosing, among other things, that on May 12, 2025, the Company dismissed CBIZ CPAs P.C. as the Company’s independent registered public accounting firm, and notified Baker Tilly US, LLP (“Baker Tilly”) of its formal decision to engage Baker Tilly to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective beginning with the review of the Company’s condensed consolidated financial statements for the quarter ending June 30, 2025, and subject to completion of Baker Tilly’s client acceptance procedures.

    This Report is being filed now that Baker Tilly has completed its client acceptance procedures. This Report does not amend or change any of the information previously disclosed in the Original Form 8-K.

    Item 4.01              Changes in Registrant's Certifying Accountant.

    Baker Tilly has completed its client acceptance procedures as referenced in the Original Form 8-K, and the Company and Baker Tilly entered into an engagement letter on May 20, 2025. There have been no changes to the disclosures regarding consultations, reports, disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K and the related instructions) related to the Company and Baker Tilly from those in the Original Form 8-K.
    2

    3
    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    SANUWAVE HEALTH, INC.
    Dated: May 21, 2025By:/s/ Peter Sorensen
    Name:Peter Sorensen
    Title:Chief Financial Officer
    3
    Get the next $SNWV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNWV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNWV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sanuwave Announces Q1 FY2025 Financial Results

      Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 202

      5/9/25 6:00:00 AM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results

      EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795 Materials for the conference call will b

      5/5/25 5:00:00 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

      SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue increased between 57% and 61% compared to Q1 2024. UltraMIST revenues for Q1 2025 increased by more than 65% versus Q1 2024 and accounted for approximately 99% of the Company's total revenues. EDEN PRAIRIE, Minn., April 08, 2025 (GLOBE NEWSWIRE) --  SANUWAVE Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2025 are expected to be

      4/8/25 8:30:00 AM ET
      $SNWV
      Medical/Dental Instruments
      Health Care

    $SNWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Sci. and Tech. Officer Cioanta Iulian exercised 3,639 shares at a strike of $15.70 and sold $114,992 worth of shares (3,639 units at $31.60) (SEC Form 4)

      4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

      5/16/25 4:48:27 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • Large owner Opaleye Management Inc. bought $203,875 worth of shares (7,998 units at $25.49) (SEC Form 4)

      4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

      4/30/25 7:06:51 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Tyler James

      4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

      4/7/25 4:14:32 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care

    $SNWV
    SEC Filings

    See more
    • Amendment: SANUWAVE Health Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K/A - SANUWAVE Health, Inc. (0001417663) (Filer)

      5/21/25 5:11:46 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • SANUWAVE Health Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - SANUWAVE Health, Inc. (0001417663) (Filer)

      5/15/25 4:06:57 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • SANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SANUWAVE Health, Inc. (0001417663) (Filer)

      5/9/25 6:08:01 AM ET
      $SNWV
      Medical/Dental Instruments
      Health Care

    $SNWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $203,875 worth of shares (7,998 units at $25.49) (SEC Form 4)

      4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

      4/30/25 7:06:51 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care

    $SNWV
    Financials

    Live finance-specific insights

    See more
    • Sanuwave Announces Q1 FY2025 Financial Results

      Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 202

      5/9/25 6:00:00 AM ET
      $SNWV
      Medical/Dental Instruments
      Health Care
    • Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results

      EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795 Materials for the conference call will b

      5/5/25 5:00:00 PM ET
      $SNWV
      Medical/Dental Instruments
      Health Care